Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.53 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.52 |
| ▸ | TUBB | P07437 | 2/20 | 0.52 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.52 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.52 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.52 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.52 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.52 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.52 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.52 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.52 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.52 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.52 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.52 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.52 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643379 | 1.00 | HSP90AA1 (0.53) | HSP90AA1TUBB4ATUBBTUBA3CTUBA1B | |
| Hydrochloric Acid SCHEMBL2774905 | 0.98 | HSP90AA1 (0.51) | HSP90AA1TUBB4ATUBBTUBA3CTUBA1B | |
| Hydrochloric Acid SCHEMBL2774907 | 0.98 | HSP90AA1 (0.51) | HSP90AA1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL21002177 | 0.85 | NPC1 (0.56) | HSP90AA1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL21002176 | 0.85 | NPC1 (0.56) | HSP90AA1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL27522303 | 0.85 | KMT2A (0.54) | KMT2ANPC1RAB9AMEN1ATM | |
| SCHEMBL27522305 | 0.85 | KMT2A (0.54) | KMT2ANPC1RAB9AMEN1ATM | |
| SCHEMBL1515148 | 0.84 | NPC1 (0.48) | HSP90AA1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2302128 | 0.81 | CA12 (0.51) | HSP90AA1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29550384 | 0.81 | CA12 (0.51) | HSP90AA1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285372-A1 | Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives | MEDCURIUS INC. (CN) | 2023-09-14 | — | — | US | disclosed |
| US-20230285372-A1 | Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives | MEDCURIUS INC. (CN) | 2023-09-14 | — | — | US | disclosed |
| WO-2021259143-A1 | PHARMACEUTICAL USE OF (E)-3-ARYLHETEROCYCLYL PROP-2-ENOIC ACID DERIVATIVES | 上海长车生物科技有限公司 | 2021-12-30 | — | — | WO | disclosed |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| EP-2970215-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| US-9650334-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| WO-2017060854-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060854-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| WO-2008046573-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES FOR USE AS BRADYKININ 1 RECEPTOR MODULATORS | Grünenthal GmbH (DE) | 2008-04-24 | — | — | WO | disclosed |
| US-7326792-B2 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1651613-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | Aventis Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014555-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-03 | — | — | US | disclosed |
| US-5624922-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0597540-B1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1996006093-A1 | 7-AZABICYCLO[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS | UNIVERSITY OF VIRGINIA (US) | 1996-02-29 | — | — | WO | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0597540-A1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1994-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | NFE2L2, KEAP1, NQO1 | HSP90AA1 1322/4885TUBB4A 1961/4885TUBB 1604/4885 |
| US-20230285372-A1 | Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives | NFE2L2, NFE2, TXNRD2 | HSP90AA1 2162/4885TUBB4A 3819/4885TUBB 4384/4885 |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | HSP90AA1 1322/4885TUBB4A 1961/4885TUBB 1604/4885 |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | P2RX3, P2RX2, P2RX5 | HSP90AA1 3294/4885TUBB4A 2149/4885TUBB 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.